Highest-materiality recent filing
MediciNova FY2025 net loss per share $0.24, operating loss $13.3M, cash down to $30.8M
Net loss attributable to shareholders $12.0M ($0.24 per share) vs $11.0M ($0.23) in FY2024.
MediciNova enters equity distribution agreement for up to $50M at-the-market offering
Agreement with Lucid Capital Markets as sales agent for at-the-market sales of common stock.
MediciNova enters $30M equity purchase agreement with Yorkville at 97% of VWAP
May sell up to $30M in common stock over 36 months via periodic advances.
Carolyn Beaver elected as Class III director with 22,024,122 votes for, 8,936,487 against, 923,050 abstain.
MediciNova updates investor presentation for March 2025 meetings
Company furnished updated slide presentation for use at investor meetings on March 11, 2025.
MediciNova stockholders re-elect two directors, ratify auditor at annual meeting
Yuichi Iwaki and Kazuko Matsuda re-elected as Class II directors; votes: 24.3M for, 7.9M against each.
MediciNova VP Geoffrey O'Brien resigns as employee, to stay as consultant
Geoffrey O'Brien, VP, retires from full-time employment effective April 2, 2024.
On March 26, 2024, Geoffrey O’Brien informed MediciNova, Inc. (the “Company”) of his decision to retire from full-time employment and resign from his employment with the Company, effective as of April 2, 2024.
Max materiality 0.65 · Median 0.40 · Most common event other_material